Cooley advised Oyster Point Pharma on the deal, while Cravath represented Viatris. Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, announced its definitive agreement to be acquired...
Viatris’ Acquisition of Oyster Point Pharma
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...